KKR has invested $95 million in Indian eyewear retail leader Lenskart via a secondary transaction that facilitated partial exits of undisclosed size for TPG Growth and TR Capital.
DAC Biotech, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised RMB1 billion ($160 million) in Series C funding led by GL Ventures, CDG Capital, and CPE.
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
The contribution CDH Investments has made to China Grand Pharma belies the size of its equity interest in the company. M&A, at home and overseas, has been central to the growth strategy
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
DCP Capital has continued its run of investments in China’s medical devices industry by participating in a Series B funding round for Hangzhou Valgen Medtech.
Wei Fu, the founder and CEO of Asia-focused healthcare investor CBC Group, has launched a special purpose acquisition company (SPAC) to pursue deals in the sector.
China-based medical devices manufacturer Hygea Medical Technology has raised a RMB500 million ($77 million) Series C round led by China Growth Capital.
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has made its first investment in an Asian healthcare company by participating in an $80 million Series C round for Indonesia healthcare technology provider Halodoc.
An investor group including Centurium Capital, CITIC Capital and Hillhouse Capital has completed its protracted pursuit of China Biologic Products Holdings with a $4.6 billion privatization.
Amazon has formed a $250 million fund that will invest in India-based small and medium-sized enterprises (SMEs) with a view to supporting nationwide business digitalization.
Fiture, a Chinese developer of artificial intelligence-enabled home fitness devices, has raised $300 million in Series B funding led by All-Stars Investment, Legend Capital, DST Global, and Coatue Management.
Arrail Group, one of China’s largest dental services providers, has raised close to $200 million in Series E funding led by Temasek Holdings.
StoneWise, a Chinese biotech start-up that uses artificial intelligence (AI) technology to develop new drugs, has raised $100 million in Series B funding across two tranches.
Embarking on its first Zoom-based fundraise, China's Long Hill Capital succeeding in closing just above target on $300 million while significantly diversifying the LP base
Brii Biosciences, a three-year-old Chinese biotech start-up that has raised approximately $415 million in private funding from the likes of Sequoia Capital China, Boyu Capital, and Yunfeng Capital, has filed for a Hong Kong IPO.
Suzhou Abogen Biosciences, a Chinese mRNA vaccine provider, has raised RMB600 million ($92 million) led by PICC Capital - an investment unit under People’s Insurance Company of China - and state-backed SDIC Venture Capital.
Baring Private Equity Asia has invested $100 million in Hutchison China MediTech (HutchMed), a US and London-listed drug discovery business that has two fully commercialized oncology products in China.
Prosus Ventures and TPG Growth have co-led a $350 million Series E round for India’s API Holdings, best known as the parent of pharmacy portal PharmEasy.
Long Hill Capital closed its third US dollar-denominated fund at $300 million with a remit to pursue healthcare and longevity-related opportunities, which includes start-ups focused on wellness and services aimed at aging consumers.
Creador has completed a third exit – with a 3.7x multiple and a 32% IRR – from its third South and Southeast Asia-focused fund, selling a minority position in Indian pharmaceutical company Corona Remedies to ChrysCapital.
L Catterton has invested JPY20 billion ($182 million) in PHC Holdings Corporation, a Japanese healthcare business – formerly known as Panasonic Healthcare – backed by KKR.